Market analysts project the GLP-1 receptor agonist aesthetic-care segment—encompassing semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) used off-label for body contouring and weight management—will reach $2 billion by 2030. The category reflects growing patient interest in pharmacologic body composition optimization alongside traditional injectables and energy-device procedures.
Market
GLP-1 Aesthetic Care Market Projected to Reach $2B by 2030 — New Revenue Stream for Medspa Operators
Semaglutide and tirzepatide demand is creating a new aesthetic-adjacent category; practices are positioning to capture it.
GLP-1 aesthetic care is projected to reach $2 billion by 2030, creating a new revenue stream for practices willing to navigate the compliance landscape.
For medspa owners, GLP-1 aesthetics represents an adjacent revenue stream and patient-acquisition lever. Practices offering semaglutide or tirzepatide consultations can cross-sell RF body tightening, cryolipolysis, or injectable chin/jawline contouring to patients seeking comprehensive body transformation. However, regulatory and compliance risks are material: GLP-1s are prescription medications requiring physician oversight, and off-label use for aesthetics sits in a gray zone. Practices must ensure proper medical supervision, informed consent, and documentation. The $2 billion projection assumes mainstream adoption; actual realization depends on insurance coverage, regulatory clarity, and competitive entry by primary-care and weight-loss clinics.
Source: original report ↗
Frequently asked questions
Can medspa practices legally prescribe semaglutide and tirzepatide for aesthetics?
GLP-1s are prescription medications requiring physician oversight, and off-label use for aesthetics sits in a regulatory gray zone. Practices must ensure proper medical supervision, informed consent, and documentation to operate compliantly, though the regulatory landscape remains unsettled.
How much will the GLP-1 aesthetic market be worth by 2030?
Market analysts project the GLP-1 receptor agonist aesthetic-care segment will reach $2 billion by 2030, encompassing semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) used for body contouring and weight management.
What procedures can medspa owners cross-sell with GLP-1 treatments?
Practices offering semaglutide or tirzepatide consultations can cross-sell RF body tightening, cryolipolysis, or injectable chin and jawline contouring to patients seeking comprehensive body transformation.
What are the main compliance risks for medspa GLP-1 programs?
Off-label GLP-1 use for aesthetics requires physician oversight, informed consent, and thorough documentation. Practices must ensure proper medical supervision to mitigate regulatory exposure in this emerging category.
Will insurance cover GLP-1 treatments at medspa practices?
Insurance coverage remains uncertain and is a key variable affecting the $2 billion market projection. Actual market realization depends on insurance coverage decisions, regulatory clarity, and competitive entry by primary-care and weight-loss clinics.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.